Additional control studies in a HER2-negative/CAV1-positive MDA-MB-231 orthotopic mammary fat pad model demonstrated that 89Zr-labeled pertuzumab accumulation does not increase on lovastatin treatment in a HER2-negative tumor model (Supplemental Figs. 5 and 6). Here, ERBB2 is linked to neoplasm.